Retail Equity Research



ICICI Prudential Life Insurance Co. Ltd.

BUY

Sector: Life Insurance 30th October, 2025

Key Chang	_{jes} Target		Rating	E	arnings 🔻	Target	Rs. 696
Stock Type	Bloomberg Code	Sensex	NSE Code	BSE Code	Time Frame	CMP	Rs. 601
Mid Cap	IPRU:IN	84,997	ICICIPRULI	540133	12 Months	Return	+16%

Data as of: 29-Oct-2025, 18:00 hrs

Company Data						
Market Cap (Rs. Cr)	86,945					
52 Week High — Lov		768 - 517				
Outstanding Shares (Rs. cr) 144.						
Free Float (%)			27.0			
Dividend Yield (%)		0.1				
6m average volume (cr)						
Beta			1.0			
Face value (Rs.)			10.0			
Shareholding (%)	Q4FY25	Q1FY26	Q2FY26			
D (70.0	70.0	70.0			

race value (NS.)			10.0
Shareholding (%)	Q4FY25	Q1FY26	Q2FY26
Promoters	73.0	73.0	72.9
FII's	13.3	13.1	13.2
MFs/Institutions	8.8	8.9	8.7
Public	2.7	2.8	3.0
Others	2.2	2.2	2.3
Total	100.0	100.0	100.0
Promoter Pledge	Nil	Nil	Nil
Price Performance	3 Month	6 Month	1 Year
Absolute Return	-2.2%	-0.3%	-19.9%
Absolute Sensex	4.6%	5.5%	5.8%
Relative Return	-6.9%	-5.8%	-25.7%

*over or under performance to benchmark index



Y.E March (Rs. cr)	FY25A	FY26E	FY27E
Net Premium	47,259	51,207	55,902
Growth (%)	13.2	8.4	9.2
New Business (%)	22.8	24.8	25.7
Net Profit	1,186	1,527	1,826
Growth (%)	39.4	28.8	19.6
EPS (Rs)	8.2	10.6	12.6
Growth (%)	38.5	29.4	19.6
BVPS (Rs)	82.6	87.7	88.7
EVPS (Rs)	332.1	379.4	435.2
RoE	9.9	12.1	14.3
RoEV	13.1	14.5	15.0
P/E	69.3	55.6	46.5
P/EV	1.7	1.5	1.3
Solvency (%)	212.2	210.2	208.2

Sustainable Growth; GST Reforms to be Beneficial

ICICI Prudential Life Insurance Co Ltd (IPRU), a joint venture between ICICI Bank and Prudential Corp Holdings, offers life, health and pension products.

- Net premium income surged 10% in Q2FY26 to Rs. 11,843cr, primarily due to a 10% YoY growth in renewal premium and 25% YoY growth in single premium.
- Annual premium equivalent (APE) in H1FY26 decreased 4.1% YoY to Rs. 4,286cr, driven by a 10.7% fall in linked products and a 50.1% drop in annuity products.
- Value of new business (VNB) fell a modest 0.9% YoY to Rs. 1,049cr in H1FY26.
 However, VNB margin increased to 24.5% from 23.7% in H1FY25, mainly due to a
 favourable business mix, improved product profitability and a favourable yield
 curve, albeit partially offset by the impact of GST on commissions and operating
 expenses.
- Consolidated profit after tax rose 17.9% YoY to Rs. 296cr in Q2FY26, primarily driven by higher investment income from shareholder funds (+151.4% YoY).
- IPRU pension fund manager subscribers totaled 10.33 lakh in Q2FY26, up 19% YoY from 8.67 lakh in Q2FY25, while assets under management increased 35% YoY to Rs. 53,040cr.

Outlook & Valuation

IPRU displayed a sustainable growth trajectory, driven by its diversified product portfolio, consistent profitability and customer-centric approach. The company is well-positioned to capitalise on the benefits of GST reforms, leveraging its strong brand, innovative products and efficient distribution network to deliver long-term business growth and increase its VNB. The company's focus on cost optimisation initiatives to streamline its operations and align its cost structure with customer demands strengthens its competitive edge. As it deepens its distribution channel and penetrates further into micro markets, its ability to adapt to changing economic conditions will become increasingly pronounced and seamless. Hence, we have retained our BUY rating on the stock with a revised target price of Rs. 696 based on 1.6x FY27E P/EV.

Quarterly Financials Consolidated


Rs.cr	Q2FY26	Q2FY25	YoY (%)	Q1FY26	QoQ (%)	H1FY26	H1FY25	YoY (%)
Premium earned (Net)	11,843	10,754	10.1	8,503	39.3	20,346	18,629	9.2
Total income	12,016	25,008	-52.0	25,320	-52.5	37,336	50,466	-26.0
Total expenses	11,484	24,898	-53.9	24,897	-53.9	36,381	50,060	-27.3
Surplus (Post tax)	485	93	422.9	376	28.9	861	377	128.4
PBT	342	285	20.1	343	-0.3	686	544	26.0
Reported PAT	296	251	17.9	301	-1.7	597	475	25.6
Adj. EPS (Rs.)	2.0	1.7	16.7	2.1	-1.9	4.1	3.3	24.6




Key Concall Highlights

- The government's recent GST reforms have made life insurance more affordable and accessible to customers. With the GST exemption,
 policyholders enjoy significant savings on premiums, increasing the attractiveness of life insurance across various income groups. This is
 expected to drive deeper insurance penetration, particularly in underserved markets.
- Under the savings segment, non-linked savings business grew 11.9% YoY in Q2FY26, which was driven by customers seeking to secure high yields in a declining interest rate environment, opting for non-par products, whereas the linked business saw an 8.6% YoY decline in Q2FY26.
- APE for the overall protection business at Rs. 419cr was relatively flat in Q2FY26, while that for the retail protection business grew 2.4%
 YoY. The changes in GST are expected to make retail products more affordable and attractive to customers.
- The estimated impact on the existing book due to the withdrawal of input tax credit on individual businesses is around 1% on embedded
 value, and to mitigate such an effect on new business profitability, multiple measures are being taken, including the renegotiation of commissions with distributors and the optimisation of operating expenses.
- The cost-to-premium ratio (overall) for H1FY26 improved to 19.2%, down 280 bps, and the cost-to-premium in the savings business also fell 280 bps to 12.7%. IPRU is focused on sustainable cost reduction measures, including controlling discretionary spending, reassigning staff and optimising digital processes, viewing these as long-term improvements rather than short-term cuts.


Net Premium



Persistency Ratio



Embedded Value



*Note: The Embedded Value for H1FY26 is compared to the FY25 figure.

PAT 480 400 320 240 160 80 2.4% 43.2% 17.9% 20% 1-10%

Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26

PAT (Rs.cr) ——Growth (YoY)

-40%

Change in Estimates

	Old estir	nates	New esti	imates	Chang	je (%)
Year / Rs cr	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Premium earned (net)	52,879	59,406	51,207	55,902	-3.2	-5.9
Profit before tax	1,431	2,277	1,660	1,985	16.0	-12.8
Net Profit	1,316	2,095	1,527	1,826	16.0	-12.8
EPS	9.1	14.5	10.6	12.6	16.5	-12.8



Consolidated Financials

Policyholder's Profit & Loss Account

Y.E March (Rs cr)	FY23A	FY24A	FY25A	FY26E	FY27E
Net Premium	38,560	41,760	47,259	51,207	55,902
% change	6.2	8.3	13.2	8.4	9.2
Income from Inv.	9,965	46,550	22,819	24,890	27,574
Transfer of funds from shareholder's account	1,802	1,802	318	200	170
Other income	152	205	223	303	418
Total Income	50,478	90,317	70,620	76,600	84,064
Commission	1,864	3,722	4,859	4,979	5,044
Operating Expenses	4,583	4,136	3,972	4,022	4,203
Other Expenses	724	617	695	811	859
Operating Profit	43,307	81,842	61,094	66,789	73,958
% change	-24.7	89.0	-25.4	9.3	10.7
Benefits Paid (Net)	30,789	39,746	45,471	45,960	46,235
Change in Reserves	9,817	40,639	13,571	18,690	24,336
Tax	184	108	250	247	458
Tax Rate (%)	7.4	9.0	18.7	18.0	18.0
Surplus/Deficit	2,302	1,089	1,090	1,125	2,088
% change	5.1	-52.7	0.0	3.3	85.5

Shareholder's Profit & Loss Account

Y.E March (Rs cr)	FY23A	FY24A	FY25A	FY26E	FY27E
Transfer from Technical A/c	2,016	1,472	1,093	1,182	1,305
Investment Inc.	880	1,373	699	909	1,091
Total Income	2,910	2,877	1,823	2,126	2,435
% change	<i>-8.7</i>	-1.1	-36.6	16.6	14.5
Other Expenses	207	154	174	266	280
Contri to Technical A/c	1,802	1,802	318	200	170
Total Expenses	2,010	1,957	492	466	449
PBT	900	921	1,332	1,660	1,985
% change	13.3	2.2	44.7	24.6	19.6
Tax	87	70	146	133	159
Tax Rate (%)	9.6	7.6	11.0	8.0	8.0
Reported PAT	813	851	1,186	1,527	1,826
Adj*					
Adj PAT	813	851	1,186	1,527	1,826
% change	7.2	4.6	39.4	28.8	19.6
No. of shares (cr)	144	144	144	144	144
Adj EPS (Rs)	5.7	5.9	8.2	10.6	12.6
% change	7.4	4.2	38.5	29.4	19.6
DPS (Rs)	0.6	0.6	0.9	1.1	1.3

Balance Sheet

V E March (De ar)	EVOCA	EV24A	EVOEA	EVACE	EV07E
Y.E March (Rs cr)	FY23A	FY24A	FY25A	FY26E	FY27E
Source of Funds					
Share Capital	1,439	1,441	1,445	1,445	1,445
Reserves & Sur- plus	8,371	9,218	10,555	11,147	11,282
Fair Value Change	280	345	-67	73	81
Shareholders' Fund	10,090	11,005	11,934	12,665	12,808
Policy Liabilities	234,365	275,004	288,576	354,713	438,254
Others	4,033	6,227	7,047	7,751	8,526
Policyholders' Fund	238,398	281,232	295,622	362,464	446,781
Funds for Future appropriations	1,669	1,287	1,283	1,227	2,010
Total	250,157	293,523	308,839	376,356	461,599
Application of					
Funds					
	9,847	10,567	14,040	14,181	14,330
Funds Shareholders' Policyholders'	9,847 94,311	10,567 114,318	14,040 128,699	14,181 156,270	14,330 189,506
Funds Shareholders'			,	,	,
Funds Shareholders' Policyholders' Assets held to cover linked liabili-	94,311	114,318	128,699	156,270	189,506
Funds Shareholders' Policyholders' Assets held to cover linked liabilities	94,311 144,058	114,318 164,842	128,699 161,240	156,270 199,753	189,506 250,338
Funds Shareholders' Policyholders' Assets held to cover linked liabilities Loans	94,311 144,058 1,314	114,318 164,842 1,761	128,699 161,240 2,419	156,270 199,753 2,613	189,506 250,338 2,848
Funds Shareholders' Policyholders' Assets held to cover linked liabilities Loans Fixed assets	94,311 144,058 1,314 596	114,318 164,842 1,761 719	128,699 161,240 2,419 848	156,270 199,753 2,613 954	189,506 250,338 2,848 1,070
Funds Shareholders' Policyholders' Assets held to cover linked liabilities Loans Fixed assets Net Current assets	94,311 144,058 1,314 596 30	114,318 164,842 1,761 719 1,314	128,699 161,240 2,419 848 1,591	156,270 199,753 2,613 954 2,584	189,506 250,338 2,848 1,070 3,505

Ratios

Y.E March	FY23A	FY24A	FY25A	FY26E	FY27E
Per Share (Rs.)					
EPS	5.7	5.9	8.2	10.6	12.6
DPS	0.6	0.6	0.9	1.1	1.3
EVPS	247.7	293.9	332.1	379.4	435.2
Earnings (%)					
RoE	8.3	8.0	9.9	12.1	14.3
RoEV	17.4	14.1	13.1	14.5	15.0
Valuation (x)					
P/E (x)	77.1	103.4	69.3	55.6	46.5
P/EV (x)	1.8	2.1	1.7	1.5	1.3
Div. Yield (%)	0.1	0.1	0.2	0.2	0.2
Exps. (% of premium)					
Commission	4.8	8.9	10.3	9.7	9.0
Operating Expenses	11.9	9.9	8.4	7.9	7.5
Total Expenses	18.6	20.3	20.2	19.2	18.1
Margin (%)					
New Business	32.0	24.6	22.8	24.8	25.7
Solvency (%)					
Solvency	208.9	191.8	212.2	210.2	208.2



Recommendation Summary -(last 3 years)



Dates	Rating	Target
29-Jan-24	BUY	549
10-May-24	BUY	670
31-0ct-24	HOLD	809
5-Feb-25	BUY	692
16-May-25	BUY	678
30-Oct-25	BUY	696

Investment Rating Criteria

Ratings	Large caps	Midcaps	Small Caps
Buy	Upside is above 10%	Upside is above 15%	Upside is above 20%
Accumulate	-	Upside is between 10%-15%	Upside is between 10%-20%
Hold	Upside is between 0% - 10%	Upside is between 0%-10%	Upside is between 0%-10%
Reduce/sell	Downside is more than 0%	Downside is more than 0%	Downside is more than 0%

Not rated/Neutral

Buy: Acquire at Current Market Price (CMP), with the target mentioned in the research note; Accumulate: Partial buying or to accumulate as CMP dips in the future; Hold: Hold the stock with the expected target mentioned in the note.; Reduce: Reduce your exposure to the stock due to limited upside.; Sell: Exit from the stock; Not rated/Neutral: The analyst has no investment opinion on the stock.

Symbols definition:







Downgrade

To satisfy regulatory requirements, we attribute 'Accumulate' as Buy and 'Reduce' as Sell.

The recommendations are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/ return/lack of clarity/event we may revisit rating at appropriate time. Please note that the stock always carries the risk of being upgraded to BUY or downgraded to a HOLD, REDUCE or SELL.

Not rated/Neutral- The analyst has no investment opinion on the stock under review.

DISCLAIMER & DISCLOSURES

Certification: I, Antu Eapan Thomas, author of this Report, hereby certify that all the views expressed in this research report reflect our personal views about any or all of the subject issuer or securities. This report has been prepared by the Research Team of Geojit Investments Limited, hereinafter referred to as GIL. For general disclosures and disclaimer: Please Click here

CRISIL has provided research support in preparation of this research report and the investment rational contained herein along with financial forecast. The target price and recommendation provided in the report are strictly GIL's views and are NOT PROVIDED by CRISIL. Further, CRISIL expresses no opinion on valuation and the associated recommendations. CRISIL has no financial liability whatsoever, to the subscribers / users of this report.

Regulatory Disclosures:

Group companies/ Fellow subsidiaries of Geojit Investments Ltd (GIL) are Geojit Financial Services Limited (GFSL), Geojit Technologies Private Limited (Software Solutions provider), Geojit Credits Private Limited (NBFC), Geojit Financial Services Ltd, Geojit IFSC Ltd (a company incorporated under IFSC Regulations), Qurum Business Group Geojit Securities LLC (a subsidiary of holding company in Oman engaged in Financial Services), Barjeel Geojit Financial Services LLC (a joint venture of holding company in UAE engaged in Financial Services), and BBK Geojit Consultancy and Information KSC (C) (a joint venture in Kuwait-engaged in Financial services). In the context of the SEBI Regulations on Research Analysts (2014), GIL affirms that we are a SEBI registered Research Entity and in the course of our business as a stock market intermediary, we issue research reports / research analysis etc. that are prepared by our Research Analysts. We also affirm and undertake that no disciplinary action has been taken against us or our Analysts in connection with our business activities

nary action has been taken against us or our Analysts in connection with our business activities.

In compliance with the above-mentioned SEBI Regulations, the following additional disclosures are also provided which may be considered by the reader before making an investment decision:

1. Disclosures regarding Ownership:

- (ii)It/its associates have no financial interest or any other material conflict in relation to the subject company (ies) covered herein, at the time of publication of the research report.

 (iii)It/its associates have no actual beneficial ownership of 1% or more in relation to the subject company (ies) covered herein, at the end of the month immediately preceding the date of publication of the research report. Further, the Analyst confirms that:
- (i) He, his associates and his relatives shall take reasonable care to ensure that they do not have any financial interest in the subject company (ies) covered herein, and they have no other material conflict in the subject company, at the time of publication of the research report.

 (ii) He, his associates and his relatives have no actual/beneficial ownership of 1% or more in the subject company covered, at the end of the month immediately preceding the date of publication of the research report.

2. Disclosures regarding Compensation:

During the past 12 months, GIL or its Associates:

- (a) It/its associates, are not in receipt of compensation from the subject company details of which are described further below: (b) Have not managed or co-managed public offering of securities for (a) Into associates, are not in receipt or co-managed public orienting of sectionics for the subject company (c) Have not received any compensation for investment banking or merchant banking or brokerage services from the subject company. (d) However, GFSL (Holding company of GIL) has received compensation for products or services other than investment banking or merchant banking or brokerage services from subject company. GFSL is engaged in the distribution of insurance products/ Mutual fund products and has derived commissions for the distribution services it has rendered to the Subject Company.

 e) Have not received any compensation or other benefits from the subject company or third party in connection with the research report (f) The subject company is / was not a client during twelve months preceding the date of distribution of the research report.

 3. Disclosure by GIL regarding the compensation paid to its Research Analyst:

- GIL hereby confirms that no part of the compensation paid to the persons employed by it as Research Analysts is based on any specific brokerage services or transactions pertaining to trading in securities of companies contained in the Research Reports.
- 4. Disclosure regarding the Research Analyst's connection with the subject company: It is affirmed that I, Antu Eapan Thomas, Research Analyst (s) of GIL have not served as an officer, director or employee of the subject company.

- employee or the subject company.

 5. Disclosure regarding Market Making activity: Neither GIL/its Analysts have engaged in market making activities for the subject company.

 6. Mr. Radharkishann Nair, Non-Executive Independent Director of GIL is currently serving in the board of ICICI Prudential Life Insurance Company Ltd as an Independent Director. This report has been prepared independently by the equity research team of GIL; the views expressed are solely the responsibility of the respective Analyst/Research Department.

 7. Disclosure regarding conflict of interests: GIL shall abide by the applicable regulations/ circulars/ directions specified by SEBI and Research Analyst Administration and Supervisory Body (RAASB) from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. GIL will endeavour to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.

 8. "Registration granted by SEBI membership of RASI (in case of IAs) and extilination from AISA in a supervisory supervisory
- 8. "Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to
- 9. Clients are required to keep contact details, including email id and mobile number/s updated with the GIL at all times.

 10. In the course of providing research services by GIL, GIL cannot execute/carry out any trade (purchase/sell transaction) on behalf of, the client. Thus, the clients are advised not to permit GIL to execute any trade on their benalf.

 11. GIL will never ask for the client's login credentials and OTPs for the client's Trading Account Demat Account and Bank Account. The Clients are advised not to share such information with anyone
- including GIL.

12.Standard Warning: "Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

13. Disclosures regarding Artificial Intelligence tools: Neither Geojit Investments Limited nor its Analysts have utilized any AI tools in the preparation of the research reports.

Please ensure that you have read the "Risk Disclosure Documents for Capital Market and Derivatives Segments" as prescribed by the Securities and Exchange Board of India before invest-

Geojit Investments Ltd. Registered Office: 7th Floor 34/659-P, Civil Line Road, Padivattom, Kochi-682024, Kerala, India. Phone: +91 484-2901000, Website: www.geojit.com/GIL. For investor queries: customercare@geoiit.com GRIEVANCES

Step 1: The client should first contact the RA using the details on its website or following

contact details: Compliance officer: Ms. Indu K. Address: 7th Floor, 34/659-P, Civil Line Road, Padivattom, Ernakulam,; Phone: +91 484-2901367; Email: compliance@geojit.com. For Grievances:grievances@geojit.com. Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at https://smartodr.in

Corporate Identity Number: U66110KL2023PLC080586, Research Entity SEBI Reg No: INH000019567; Depository Participant: IN-DP-781-2024.